A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.

ABSTRACT:

Introduction

End-user perspectives are vital to the design of new biomedical HIV prevention products. Conjoint analysis can support the integration of end-user perspectives by examining their preferences of potential pre-exposure prophylaxis (PrEP) products. The Microbicides Trial Network (MTN) 035 protocol examined three placebo rectal dosage forms (insert, enema and suppository) that could deliver PrEP prior to receptive anal sex (RAS).

Methods

Between April 2019 and July 2020, we enrolled 217 HIV-negative, cisgender men who have sex with men (MSM; n = 172; 79.3%) and transgender people (n = 47; 20.7%) ages 18-35 into a randomized cross-over trial across Malawi, Peru, South Africa, Thailand and the United States. Participants used each product prior to RAS over 4-week peri

SUBMITTER: Bauermeister J 

PROVIDER: S-EPMC10945032 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature